BRKR moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 76%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BRKR as a result. In 69 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for BRKR turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 26 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for BRKR crossed bullishly above the 50-day moving average on September 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 201 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
BRKR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.049) is normal, around the industry mean (10.930). P/E Ratio (74.885) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.052). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
VIVO saw its Momentum Indicator move below the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 76 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for VIVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 42 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
VIVO moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVO advanced for three days, in 187 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
VIVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.716) is normal, around the industry mean (17.861). P/E Ratio (35.336) is within average values for comparable stocks, (159.605). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (104.490).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
BRKR | VIVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 100 | |
PRICE GROWTH RATING 1..100 | 39 | 87 | |
P/E GROWTH RATING 1..100 | 5 | 5 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (59) in the Medical Specialties industry is in the same range as VIVO (90) in the Biotechnology industry. This means that BRKR’s stock grew similarly to VIVO’s over the last 12 months.
BRKR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as VIVO (100) in the Biotechnology industry. This means that BRKR’s stock grew similarly to VIVO’s over the last 12 months.
BRKR's SMR Rating (92) in the Medical Specialties industry is in the same range as VIVO (100) in the Biotechnology industry. This means that BRKR’s stock grew similarly to VIVO’s over the last 12 months.
BRKR's Price Growth Rating (39) in the Medical Specialties industry is somewhat better than the same rating for VIVO (87) in the Biotechnology industry. This means that BRKR’s stock grew somewhat faster than VIVO’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is in the same range as VIVO (5) in the Biotechnology industry. This means that BRKR’s stock grew similarly to VIVO’s over the last 12 months.
| BRKR | VIVO | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Advances ODDS (%) | 10 days ago 69% | 20 days ago 85% |
| Declines ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Aroon ODDS (%) | N/A | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while VIVO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 4 TA indicator(s) are bullish while VIVO’s TA Score has 4 bullish TA indicator(s).
BRKR (@Medical/Nursing Services) experienced а -6.90% price change this week, while VIVO (@Computer Communications) price change was -32.62% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.79%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -14.87%.
The average weekly price growth across all stocks in the @Computer Communications industry was -7.83%. For the same industry, the average monthly price growth was -10.09%, and the average quarterly price growth was +3.20%.
BRKR is expected to report earnings on Oct 29, 2026.
VIVO is expected to report earnings on Dec 02, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Computer Communications (-7.83% weekly)Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VPLS | 74.20 | 0.04 | +0.05% |
| Vanguard Core Plus Bond ETF (VPLS) | |||
| SDHY | 15.11 | -0.09 | -0.59% |
| PGIM Short Duration High Yield Opportunities Fund | |||
| DMO | 9.56 | -0.06 | -0.62% |
| Western Asset Mortgage Opportunity Fund | |||
| NVBU | 31.33 | -0.37 | -1.17% |
| AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF (NVBU) | |||
| CATG | 8.67 | -0.56 | -6.07% |
| Leverage Shares 2X Long CAT Daily ETF (CATG) | |||
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with BRKRP. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then BRKRP could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -1.05% | ||
| BRKRP - BRKR | 91% Closely correlated | -0.85% | ||
| A - BRKR | 78% Closely correlated | +1.40% | ||
| MTD - BRKR | 75% Closely correlated | +0.70% | ||
| WAT - BRKR | 68% Closely correlated | +1.73% | ||
| RVTY - BRKR | 68% Closely correlated | -1.91% | ||
More | ||||